Register Login

Favorable FDA Edoxaban Vote

According to an October 30 Medscape post, Edoxaban (Savaysa, Daiichi-Sankyo) received a favorable vote, 9–1, in favor of release for once a day treatment at 30 and 60 mg to prevent non-valvular atrial fibrillation ischemic stroke. Edoxaban was found non-inferior to “in control” Coumadin in patients with mild to moderate renal impairment, but its performance in people with creatinine clearances over 80 mL/min was found to be inferior. The advisory committee vote is preliminary to FDA release of edoxaban, the final ruling could be weeks or months away.

Comments (0)
Anticoagulant Therapy

No comments here.

Leave a Reply